Aktienanalyse zu Elevance Health Inc (ELV)ELVElevance Health Inc

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Elevance Health Inc is a good buy right now due to its current price of $412.7 being below the analyst price target of $480 from BofA, indicating a potential upside of 16.3%. Additionally, the stock's RSI of 71.921 suggests it is nearing overbought territory, but the strong earnings performance with a 20.55% EPS surprise last quarter supports continued growth. The main risk is the hedge fund selling trend, which has increased by 135.25% over the last quarter, indicating potential bearish sentiment among institutional investors.